Published in Histol Histopathol on April 01, 2000
Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg (2007) 2.24
Critical role and regulation of transcription factor FoxM1 in human gastric cancer angiogenesis and progression. Cancer Res (2009) 1.96
Genomic and genetic alterations influence the progression of gastric cancer. World J Gastroenterol (2011) 1.55
HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature. J Cancer (2012) 1.54
MYC and gastric adenocarcinoma carcinogenesis. World J Gastroenterol (2008) 1.17
Pathogenetic mechanisms in gastric cancer. World J Gastroenterol (2014) 0.97
Prognostic significance of immunohistochemical expression of EGFR and C-erbB-2 oncoprotein in curatively resected gastric cancer. Cancer Res Treat (2004) 0.95
Altered expression of transcription factor Sp1 critically impacts the angiogenic phenotype of human gastric cancer. Clin Exp Metastasis (2005) 0.93
The impact of C-MYC gene expression on gastric cancer cell. Mol Cell Biochem (2010) 0.91
Increased levels of SLP-2 correlate with poor prognosis in gastric cancer. Gastric Cancer (2013) 0.90
Prognostic implications of EGFR and HER-2 alteration assessed by immunohistochemistry and silver in situ hybridization in gastric cancer patients following curative resection. Gastric Cancer (2013) 0.90
Study on the mechanism of epidermal growth factor-induced proliferation of hepatoma cells. World J Gastroenterol (2003) 0.90
Protein signatures for classification and prognosis of gastric cancer a signaling pathway-based approach. Am J Pathol (2011) 0.89
Effects of epidermal growth factor on the growth of human gastric cancer cell and the implanted tumor of nude mice. World J Gastroenterol (2002) 0.86
How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer. Oncologist (2014) 0.85
Expression of VEGF, EGFR, and IL-6 in gastric adenomas and adenocarcinomas by endoscopic submucosal dissection. Dig Dis Sci (2009) 0.83
Expression of CDC25 phosphatases in human gastric cancer. Dig Dis Sci (2007) 0.81
Identification of prognosis-related proteins in advanced gastric cancer by mass spectrometry-based comparative proteomics. J Cancer Res Clin Oncol (2008) 0.79
Signal transduction proteins in tumors from Puerto Rican and Caucasian gastric adenocarcinoma patients: expression differences with potential for specific targeted therapies. Dig Dis Sci (2008) 0.79
Antiangiogenic therapy in human gastrointestinal malignancies. Gut (2006) 0.79
A gene expression profile related to immune dampening in the tumor microenvironment is associated with poor prognosis in gastric adenocarcinoma. J Gastroenterol (2013) 0.79
Discovery and validation of an INflammatory PROtein-driven GAstric cancer Signature (INPROGAS) using antibody microarray-based oncoproteomics. Oncotarget (2014) 0.76
The prognostic value of β-catenin and LEF-1 expression in patients with operable gastric carcinoma. Am J Transl Res (2016) 0.75
Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med (1991) 7.17
Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med (1995) 6.77
Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol (1998) 5.74
The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene (2000) 4.90
Methodological issues in studies of air pollution and daily counts of deaths or hospital admissions. J Epidemiol Community Health (1996) 4.44
Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg (1998) 4.35
High-resolution serum proteomic features for ovarian cancer detection. Endocr Relat Cancer (2004) 3.75
A potential role for interleukin-7 in T-cell homeostasis. Blood (2001) 3.56
Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med (1995) 3.43
Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Hum Pathol (1990) 3.22
Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol (2001) 3.05
A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med (1999) 3.02
BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reports. J Med Genet (2008) 2.79
Osteoporosis is a toxic effect of long-term etretinate therapy. Arch Dermatol (1995) 2.78
Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat Med (1995) 2.74
Cloning of the alpha chain of human platelet glycoprotein Ib: a transmembrane protein with homology to leucine-rich alpha 2-glycoprotein. Proc Natl Acad Sci U S A (1987) 2.70
Effects of urban air pollution on emergency room admissions for chronic obstructive pulmonary disease. Am J Epidemiol (1991) 2.69
[Toxic hepatitis caused by droxicam]. Med Clin (Barc) (1992) 2.69
Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet (2000) 2.66
p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene (1992) 2.64
Time-series analysis of air pollution and cause-specific mortality. Epidemiology (1998) 2.60
A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg (1987) 2.54
A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med (1989) 2.46
The screening histories of women with invasive cervical cancer, Connecticut. Am J Public Health (1995) 2.43
Use of complementary medicine by adult patients participating in cancer clinical trials. Oncol Nurs Forum (2000) 2.41
CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy. Ann Intern Med (1991) 2.35
Nonbacterial thrombotic endocarditis: a review. Am Heart J (1987) 2.34
Granulocyte colony-stimulating factor as a marker for bacterial infection in neonates. J Pediatr (1996) 2.27
Subthalamic deep brain stimulation at individualized frequencies for Parkinson disease. Neurology (2012) 2.18
Pre-injury neuro-psychiatric medication use, alone or in combination with cardiac medications, may affect outcomes in trauma patients. J Postgrad Med (2014) 2.16
Y chromosome microdeletions and alterations of spermatogenesis. Endocr Rev (2001) 2.07
A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res (2001) 2.05
Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol (1995) 2.02
Simian virus-40 large-T antigen binds p53 in human mesotheliomas. Nat Med (1997) 2.01
Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Ann Oncol (2013) 1.92
Assessment of left atrial appendage function by biplane transesophageal echocardiography in patients with nonrheumatic atrial fibrillation: identification of a subgroup of patients at increased embolic risk. J Am Coll Cardiol (1994) 1.91
Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med (1988) 1.90
Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. Cancer J Sci Am (2006) 1.89
Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer Institute. J Clin Oncol (1992) 1.89
Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet (2005) 1.85
Peripheral airway cell marker expression in non-small cell lung carcinoma. Association with distinct clinicopathologic features. Am J Clin Pathol (1992) 1.84
Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue. Am J Pathol (1990) 1.82
Perioperative blood transfusions are associated with decreased time to recurrence and decreased survival after resection of colorectal liver metastases. Ann Surg (1988) 1.81
Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol (1998) 1.80
Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol (1999) 1.78
Tolerance to tumor necrosis factor in rats and the relationship to endotoxin tolerance and toxicity. J Exp Med (1988) 1.78
Obesity and therapy-related toxicity in patients treated for small-cell lung cancer. J Natl Cancer Inst (1995) 1.76
Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer. J Clin Oncol (1992) 1.74
The impact of deep brain stimulation on executive function in Parkinson's disease. Brain (2000) 1.74
Early tracheostomy for primary airway management in the surgical critical care setting. Surgery (1990) 1.73
Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients. Brain (2008) 1.70
References values for forced spirometry. Group of the European Community Respiratory Health Survey. Eur Respir J (1998) 1.68
Pancreatic-phase versus portal vein-phase helical CT of the pancreas: optimal temporal window for evaluation of pancreatic adenocarcinoma. AJR Am J Roentgenol (1999) 1.67
Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. Int J Cancer (1998) 1.65
Involvement of the human pedunculopontine nucleus region in voluntary movements. Neurology (2010) 1.60
In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. J Clin Oncol (1994) 1.60
Squamous cell carcinoma of the thyroid: an aggressive tumor associated with tall cell variant of papillary thyroid carcinoma. Mod Pathol (2000) 1.59
Long-term visual changes following pituitary irradiation. Int J Radiat Oncol Biol Phys (1995) 1.58
Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol (1999) 1.58
Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease. J Clin Invest (1998) 1.58
Identical allelic loss on chromosome 11q13 in microdissected in situ and invasive human breast cancer. Cancer Res (1995) 1.57
Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy. J Infect Dis (1995) 1.56
Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease. Postmenopausal Estrogen/Progestin Interventions Trial. N Engl J Med (1997) 1.55
Tumor recurrence in stage I ovarian serous neoplasms of low malignant potential. Int J Gynecol Pathol (1998) 1.54
Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res (1987) 1.54
Multiple facial angiofibromas and collagenomas in patients with multiple endocrine neoplasia type 1. Arch Dermatol (1997) 1.53
Intracystic papillary carcinoma of the breast. After mastectomy, radiotherapy or excisional biopsy alone. Cancer (1983) 1.53
Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J Clin Oncol (2001) 1.52
Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood (1997) 1.52
Molecular and cellular characterization of human renal cell carcinoma cell lines. Cancer Res (1992) 1.52
A prospective randomized trial evaluating colloid versus crystalloid resuscitation in the treatment of the vascular leak syndrome associated with interleukin-2 therapy. J Immunother Emphasis Tumor Immunol (1994) 1.49
Study of physiological availability of temazepam in man. Int J Clin Pharmacol (1972) 1.49
Retained surgical foreign bodies: a comprehensive review of risks and preventive strategies. Scand J Surg (2009) 1.49
Malignant lymphomas involving the ovary. A clinicopathologic analysis of 39 cases. Am J Surg Pathol (1993) 1.48
NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight. Neurology (2007) 1.47
Papillary endothelial hyperplasia in the thyroid following fine-needle aspiration. Arch Pathol Lab Med (1991) 1.46
Immunohistochemical analysis of cathepsins D, B, and L in human breast cancer. Hum Pathol (1994) 1.45
Identical genetic changes in different histologic components of Wilms' tumors. J Natl Cancer Inst (1997) 1.44
Severe endocrine and nonendocrine manifestations of the McCune-Albright syndrome associated with activating mutations of stimulatory G protein GS. J Pediatr (1993) 1.43
Signet ring carcinoma of the female breast: a clinicopathologic analysis of 24 cases. Cancer (1981) 1.42
Correlation of in vitro drug-sensitivity testing results with response to chemotherapy and survival in extensive-stage small cell lung cancer: a prospective clinical trial. J Natl Cancer Inst (1990) 1.42
Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. Clin Infect Dis (1992) 1.42
Utilization of microdissection and the polymerase chain reaction for the diagnosis of adrenal cortical carcinoma in fine-needle aspiration cytology. Cancer (1999) 1.39
Immunohistochemical detection of P-glycoprotein in Ewing's sarcoma and peripheral primitive neuroectodermal tumors before and after chemotherapy. Am J Clin Pathol (1994) 1.39
[Central venous catheter location by endocavitary ECG: an alternative to chest radiography]. Med Clin (Barc) (1997) 1.39
Molecular analysis of genetic changes in the origin and development of renal cell carcinoma. Cancer Res (1991) 1.38
Incidence of loss of heterozygosity at p53 and BRCA1 loci in serous surface carcinoma. Hum Pathol (1999) 1.37
Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas. J Clin Oncol (1988) 1.37
2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. J Infect Dis (1993) 1.37
Characterization of a human astrovirus serotype 2 structural protein (VP26) that contains an epitope involved in virus neutralization. Virology (1994) 1.37
ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res (1991) 1.36
Distinct phenotypes of antigen-selected CD8 T cells emerge at different stages of an in vivo immune response. J Immunol (1995) 1.35
Concordance of genetic alterations in poorly differentiated colorectal neuroendocrine carcinomas and associated adenocarcinomas. J Natl Cancer Inst (1997) 1.35
EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol (1993) 1.34
Chemosensitivity testing of human colorectal carcinoma cell lines using a tetrazolium-based colorimetric assay. Cancer Res (1987) 1.34
Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. J Thorac Cardiovasc Surg (1998) 1.33